11/19/2019 7:22:38 AM
RedHill Biopharma Q3 Net Revenues $1.4 Mln Vs $1.6 Mln Last Quarter
10/18/2019 6:09:07 AM
RedHill Announces $36 Mln Strategic Investment By Cosmo Pharma And U.S. Rights To Approved Travelers’ Drug AEMCOLO
9/26/2019 8:21:09 AM
RedHill Biopharma Provides H2 R&D Update
9/26/2019 8:08:49 AM
RedHill Biopharma Provides H2 R&D Update
7/12/2019 7:20:43 AM
WBB Securities Raises RedHill Biopharma Ltd. (RDHL) To Strong Buy From Buy With $17 Price Target
7/3/2019 7:09:47 AM
RedHill Biopharma Announces FDA Acceptance Of NDA For Talicia
3/12/2019 7:44:17 AM
WBB Securities Raises RedHill Biopharma Ltd. (RDHL) To Buy From Speculative Buy With $17 Price Target
1/17/2019 8:06:36 AM
RedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA For H. Pylori Infection
12/11/2018 11:02:29 AM
RedHill Biopharma Closes $20 Mln Underwritten Offering
12/6/2018 8:49:32 AM
RedHill Biopharma Prices Public Offering For 2.86 Mln ADSs At $7.00 Per ADS
12/3/2018 7:24:50 AM
RedHill Reports Positive Top-Line Results From Confirmatory Phase 3 Study With TALICIA For H. Pylori Infection
11/13/2018 7:10:43 AM
RedHill Biopharma Q3 Loss Per Share $0.04 Vs $0.09 Last Year
10/22/2018 9:30:20 AM
RedHill Biopharma Announces Addl Data From Positive Phase III Study Of RHB-104 In Crohn’s Disease
10/10/2018 7:09:22 AM
RedHill Biopharma To Present Late-Breaking Abstract On Positive Phase III Crohn’s Disease Study With RHB-104 At UEG Week
9/4/2018 7:08:45 AM
RedHill Reports Completion Of Enrollment For Confirmatory Phase III Study With TALICIA For H. Pylori Infection
8/30/2018 7:15:22 AM
RedHill Biopharma Q2 Loss/shr Narrows To $0.05 From $0.06 Last Year
8/14/2018 10:16:56 AM
RedHill Biopharma Announces Closing Of $25 Mln Underwritten Offering
8/13/2018 7:06:53 AM
RedHill Biopharma Gets Allowance For New U.S. Patent Covering RHB-104 For Crohn’s Disease And RHB-204 For NTM Infections